home / stock / krys / krys news

KRYS News and Press, Krystal Biotech Inc. From 11/20/18

Stock Information
Company Name: Krystal Biotech Inc.
Stock Symbol: KRYS
Market: NASDAQ
Website: krystalbio.com
Menu
KRYS KRYS Quote KRYS Short KRYS News KRYS Articles KRYS Message Board
Get KRYS Alerts

News, Short Squeeze, Breakout and More Instantly...
KRYS - Krystal Biotech to Present at Evercore ISI HealthCONx

PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...
KRYS - Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa PITTSBURGH, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (Nasdaq: KRYS), a gene ther...

KRYS - Abeona Therapeutics: A Potential Leader In Gene Therapy

Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in...

KRYS - Gene therapy players under pressure

The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
KRYS - Krystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences

PITTSBURGH, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...

KRYS - Krystal Biotechs' KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis

KB105 is Krystal’s second "off-the-shelf" topical gene therapy candidate to receive Rare Pediatric Disease Designation for treating debilitating skin diseases PITTSBURGH, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS), a gene therapy company dedicated to...

KRYS - Chardan Capital Markets acts as Sole Placement Agent in $10 Million Securities Purchase

NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS) securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at ...
Previous 10 Next 10